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Background: To quantify the benefits (cancer prevention and down-staging) and harms (recall and excess treatment) of cervical
screening starting from age 20 years rather than from age 25 years.
Methods: We use routine screening and cancer incidence statistics from Wales (for screening from age 20 years) and England
(screening from 25 years), and unpublished data from the National Audit of Invasive Cervical Cancer to estimate the number of:
screening tests, women with abnormal results, referrals to colposcopy, women treated, and diagnoses of micro-invasive (stage 1A)
and frank-invasive (stage IBþ ) cervical cancers (under three different scenarios) in women invited for screening from age 20 years
and from 25 years.
Results: Inviting 100 000 women from age 20 years yields an additional: 119 000 screens, 20 000 non-negative results, 8000
colposcopy referrals, and an extra 3000 women treated when compared with inviting from age 25 years. Screening from age 20
years prevents between three and nine frank invasive cancers and between 0 and 23 cancers in total (depending on the scenario).
A cumulative increase of nine stage IBþ cancers corresponds to an annual rate increase of 0.9 per 100 000 women aged 20–29 years.
Conclusions: To prevent one frank invasive cancer, one would need to do between 12 500 and 40 000 additional screening tests in
the age group 20–24 years and treat between 300 and 900 women.
In October 2003, a new policy was announced concerning the age
at which women are invited for cervical screening in England.
Previously, women were to be invited at least once every 5 years
from age 20 to 64 years. The new policy required that all women
should be invited three-yearly from their 25th birthday up to age
49 years and five-yearly from age 50 to 64 years. Wales set a policy
of three-yearly screening from age 20 years in 1999 and continued
unchanged until 2013.
The age from which to start cervical screening remains
controversial. European guidelines (Arbyn et al, 2010) recommend
that screening ‘should start in the age range 20–30 years, but
preferentially not before age 25 or 30 years’. Australia starts from
age 18 years (or two years after first sexual intercourse, whichever
is later) as did America (Saslow et al, 2002). Most US guidelines
now recommend that screening starts at age 21 years regardless of
the age of onset of sexual activity (Committee on Practice
Bulletins-Gynecology, 2012; Moyer, 2012; Saslow et al, 2012),
whereas some countries with organised screening programmes
(e.g., Finland and The Netherlands) do not invite women until they
are 30 years.
Not screening young women remains unpopular. Data from
2010 show that the majority (62%) of 20-year-old women in the
United States of America are still attending cervical screening
(Centers for Disease Control and Prevention, 2013) and a poll
on the BMJ website in 2009 found that 65% (287 out of 443) of
those choosing to participate were not in favour of stopping
screening in women under age 25 years (British Medical
Journal, 2009).
Screening guidelines and policies refer to harms and benefits of
screening, but they do not provide any figures with which one
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could make an explicit comparison. Here, we aim to quantify the
harms and benefits of screening starting from age 20 years
compared with starting from age 25 years.
MATERIALS AND METHODS
We compared offering three-yearly screening in 100 000 women
starting from age 20 years with starting from age 25 years by
considering the following events: number of screening tests,
number of women with an abnormal screening test, number of
women referred to colposcopy, number of women treated (excision
or ablation), number of women with micro-invasive cervical cancer
(stage IA), and number of women with frank cervical cancer (stage
IB or worse). No attempt was made to estimate the number with
anxiety as a result of their screening, nor the number of preterm
deliveries as a result of their treatment. Our approach was to
estimate the cumulative number of events by using the relevant
proportions from published data, combining them as appropriate,
and presenting the results per 100 000 women invited for
screening.
The results are presented in terms of the cumulative number of
events over 7 years from age 20 years (until a woman’s 27th
birthday). Follow-up until age 27 years was used to ensure that
women first screened at age 25 years had time to be diagnosed
following early recall and because we reasoned that there would be
very little difference in results once at least one round of screening
had been completed under both policies. Estimation was carried
out separately in the age groups 20–24 and 25-26 years and then
summed.
We used three types of data: tabular cross-sectional statistics on
cervical screening, individual-level longitudinal data on cervical
screening, and cancer incidence statistics, from a total of six
sources. Routinely published screening data from England and
from Wales in the financial year 2011/12 (Cervical Screening
Wales, 2012; The NHS Information Centre, 2012) were used for
the number of tests taken and the result of these tests
(Supplementary Tables 1 and 2). Cancer incidence rates were
taken from national statistics (Office for National Statistics, 2013;
The Welsh Cancer Intelligence and Surveillance Unit, 2013). In
general, we used data from Wales for screening from age 20 years
and from England for screening from age 25 years. Since, however,
the change in policy in England was only implemented in
2004–2005, women born before 1984 will have been invited from
age 20 years even in England.
The number of screening tests that would be carried out, under
each policy, between ages 20 and 27 years is based on the
proportion of women with at least one adequate test result in a
given year (2011/12; see Supplementary Table 1). For Tables 1 and 2,
these proportions were multiplied by five for the age group 20–24
years. We assume that with three-yearly screening from age 25 years,
half of those screened between 25 and 29 years will be screened at
25 or 26 years. Thus, for screening from 25 years, we multiplied the
annual numbers for women aged 25–29 years by 2.5 and by 2.0 for
screening from age 20 years.
For the estimation of the non-negative test results in the age
group 25–26 years when screening starts from age 25 years, we
explicitly took into account the extent to which a first-test is more
likely to be non-negative than a test taken in a woman of the same
age who was screened previously. Although direct comparison
between England and Wales is possible, we were concerned that
this would overestimate differences in cytological abnormalities
associated with the different policies because cytological abnorm-
ality rates tend to be slightly higher (at all ages) in Wales compared
with England. Further, assuming abnormality rates in England at
ages 25–26 years (on the prevalent screen) were much higher than
at ages 27–29 years, the effect would be diluted using the available
data for ages 25–29 years combined. Using longitudinal data from
the NHS Cervical Screening Programme (NHSCSP) audit of
cervical screening in England, we estimated the relative proportion
of borderline or mild dyskaryosis in women screened from age 25
years compared with those screened from age 20 years
(Supplementary Table 5). The relative risks in Supplementary
Table 5 were calculated stratifying on year of test, to allow for the
change in the proportion of non-negative results over time, with
the strata combined using Mantel–Haenszel weights. The same was
done for moderate dyskaryosis or worse. These relative risks were
applied to the proportions with the given results in Wales so as to
estimate the results of screening from age 25 years.
In the published statistics of the cervical screening programme,
there is no age breakdown of the numbers of referrals to
colposcopy. To estimate referrals within the age groups, we
assumed that all women with a moderate or worse test result and a
certain proportion (independent of age) of women with a borderline
or mild test result are referred to colposcopy. This proportion is
estimated on the basis of a weighted average of data from England
and Wales (see Supplementary Table 1, footnote (4)).
There are no good data on the number of women treated. We
approximated the number of women treated by the number with
CIN2 or worse on histology. As there are no data on histology by
age, we assumed that the positive predictive value of a particular
cytology result for CIN2þ was the same at all ages. The predictive
values are given separately for women referred following a low-
grade result (inadequate, borderline, and mild) and women with a
potentially significant abnormality (moderate or worse cytology;
see Supplementary Table 2, footnote 4). Most women referred
following a low-grade result will have had a second such result
whilst on early recall following a first low-grade result.
Table 1. Assumptions for the estimation of excess cancers diagnosed as a result of the change in policy under various scenarios
Assumptions






A. Stage IA cancer is always occulta Yes Yes Yes
B. Observed changes in rates (relative to those age 30–34 years)
caused by the change in policy
Yes Not applicable Not applicable
C. Observed stage distribution age 25-26 years Yes Not applicable Not applicable
D. Cancer does not regress Not applicable Yes Yes
E. Progression of stage IA to IB to symptomatic IBþ cancer Not applicable Yes Yes
F. Progression of CIN3 to cancer (by age 25 years) Not applicable 0 0.2% p.a.b
aNo cases are found in the absence of screening.
bSuch a rate is consistent with historical rates of CIN3 and cervical cancer in young women in England and Scotland (see Sasieni et al, 2009b).
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In the direct comparison between Wales and England, the rates
were averaged from 2000–2011 for Wales and for 2010–2011
for England (to include only women first invited at 25 years;
Supplementary Table 3). As these are annual rates, the numbers
were multiplied by 5 to get the cumulative incidence for ages 20–24
years, and by 2 for the cumulative incidence for ages 25–26 years.
The numbers of stage 1A and stage 1Bþ cancers were calculated
by multiplying the total number of cancers by the proportion of
cancers diagnosed at the given stage for that age range. These were
estimated using cohort data from the NHSCSP audit of invasive
cervical cancer in England (Audit of Invasive Cervical Cancer
Management Group, in press) and from the Cervical Screening
Wales Audit of Cervical Cancer (Sasieni et al, 2013; Supplementary
Table 4). In the NHSCSP audit, of those cancers that were initially
registered with stage unknown but subsequently had a stage
entered, the vast majority were stage IB or worse. We therefore
pool cancers of unknown stage with frank invasive cancers for
estimation of the proportion of micro-invasive cancer.
We estimated the number of cancers with a policy of starting
screening from age 25 years under three different scenarios. A
summary of the assumptions made by each scenario can be found
in Table 1. Although about 20% of cancers in women not invited
for screening aged 20–24 years were stage 1A (unpublished audit
data), we assumed that without screening there would be no stage
IA cancers in women aged 20–24 years (assumption A).
Scenario 1 is based on the observed trends in cervical cancer.
We compared changes in rates in women aged 20–24 and 25–29
years with those in women aged 30–34 years. Scenarios 2 and 3
involve modelling progression from CIN3 to stage 1A and stage 1B
cervical cancer. In scenario 2, it is assumed that no screen-detected
CIN3 would have progressed to cancer by age 25 years (i.e., the
total number of cancers remained the same). In scenario 3, we
assume that in women aged 20–26 years, 0.2% of CIN3 progresses
to cancer each year (Sasieni et al, 2009b). For more details see the
Supplementary Methods.
Analyses were done in STATA 12 (StataCorp., College Station,
TX, USA).
RESULTS
The numbers on which estimates are based are summarised in
Supplementary Tables 1–5. The main results are presented in
Tables 2–4. Table 2 compares the observed impact of cervical
screening in 100 000 women in England andWales. Table 3 estimates
the impact of the different screening policies on workload (numbers
of screening tests, colposcopy referrals, and women treated) and
Table 4 estimates cervical cancer under various scenarios.
Numbers of tests. The number of screening tests (counting at most
one test per woman per year) in 100 000 women aged 20–26 years
is estimated to be 110 562 higher in Wales than in England
(Table 2). Ignoring tests outside of the programme and allowing for
more testing exactly at age 25 years, we estimate that the difference
that is attributable to the different policies is 119 108 (Table 3).
Non-negative results. By age 27 years, there are 30 956 non-
negative episodes per 100 000 women in Wales. By contrast, only
10 703 non-negative episodes are observed in England (Table 2;
including 1658 under age 25 years).












National statistics for 2010/11a
Screening tests 20–24 20–24 134 961 8546
25–29 25–26b 54 857 70710
Sum 189 818 79256 110562
Non-negative test results 20–24 20–24 23 968 1658
25–29 25–26 6 988 9045
Sum 30 956 10703 20253
Moderate dyskaryosis or worse 20–24 20–24 3227 270
25–29 25–26 1548 2189
Sum 4775 2459 2316
Average incidencec 2000–2011 for Wales, 2010–2011 for England
Cancers (all) 20–24 20–24 19.7 12.5
25–29 25–26d 30.8 36.7
Sum 50.5 49.2 1.3
Proportions observed in Audit datae
Cancers (stage 1A) 20–24 20–24 7.9 4.3
25–29 25–26 15.0 21.4
Sum 22.8 25.7 2.8
Cancers (stage 1Bþ ) including unknowns 20–24 20–24 11.8 8.2
25–29 25–26 15.8 15.3
Sum 27.6 23.5 4.1
aSee Supplementary Table 1.
bCumulative numbers of tests are 2 times the annual incidence rate in Wales and 2.5 times the annual incidence rate in England.
cSee Supplementary Table 3.
dCumulative number of cancers is two times the annual incidence rate (shown in Supplementary Table S3) age 25–29 for both England and Wales.
eSee Supplementary Table 4.
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Despite rates of moderate dyskaryosis or worse at age 25–29
years being higher in England than in Wales (Supplementary
Table 1), the cumulative number of women with moderate
dyskaryosis or worse by age 27 years is much greater in Wales than
in England: about 2316 more cases per 100 000 women (Table 2).
In the longitudinal audit data (Supplementary Table 5), the
proportion of results that are borderline or mild after adjusting for
year of test is 13% greater in women screened from age 25 years
compared with those screened from age 20 years; and for moderate
or worse, it is 32% greater. We applied the weighted relative risks
(1.13 and 1.32) to the Welsh proportions (Supplementary Table 1).
This yields 10 558 non-negative tests by age 27 years in 100 000
women invited from age 25 years: 20 398 fewer than when
screening is offered from age 20 years (Table 3).
Colposcopy and treatment. Overall, 33% of women with a
borderline or mild test result were referred to colposcopy (see
Supplementary Table 1, footnote (4)). Based on the numbers with
low-grade (borderline or mild) and high-grade (moderate or
worse) cytology results and referral rates of 33% for low grade and
100% for high grade, we estimate that there would be 13 427
referrals with screening from age 20 years compared with 5252
with screening from age 25 years (Table 3).
On average (see Supplementary Table 2, footnote (4)), 84% of
women with moderate or worse dyskaryosis on cytology have
CIN2 or worse histology (and we assume that they will be treated,
as per guidelines (NHS Cancer Screening Programmes, 2010)), and
17% of women referred to colposcopy with low-grade cytology
have CIN2 or worse. We thus estimate that 3885 of 100 000 women
offered screening from age 20 years would be treated under age 25
years and a further 1606 women at age 25–26 years. Offering
screening from age 25 years results in somewhat more being
treated at age 25–26 years (2657), but cumulatively reduces the
number of women treated by about 2834 per 100 000 population
(Table 3); that is, 2.8% of women avoid treatment. As only just over
half of women invited are actually screened at age 20–24 years
(54.8% of women aged 20–24 years were tested within the last 5
years in Wales in 2011/12; Cervical Screening Wales, 2012),
approximately 1 in 20 of those screened at age 20–24 years will
receive treatment that they would not otherwise have had.
Cervical cancer. The average cervical cancer rates in the age group
20–24 years between 2000 and 2011 were higher in Wales than in
England (Supplementary Table 3). Thus, cumulatively there were
some 1.3 additional cancers per 100 000 women between age 20
and 27 years in Wales than in England (Table 2).
For estimating cancers with screening from age 20 years, we use
a rate of 4 per 100 000 per year for women aged 20–24 years (which
is at the high end of what has been observed in England and
Wales) and for women aged 25–29 years, a rate of 15 per 100 000
per year (Supplementary Table 3).
The age-specific proportions of cancers that are stage IA with
screening from age 20 years are based on audit data for Wales
1999–2009 (see Supplementary Table 4). Audit data from England
for 2007–2012 yield similar results. However, more recent data from
England show a decline in the proportion of cancers that are stage IA
in women aged 20–24 years and an increase in women aged 25–29
years (see footnote (3) and (4) in Supplementary Table 4).
Despite the later start to screening in England, the observed
rates of stage IBþ cervical cancer are not greater (at ages 20–24
and 25–29 years) than those in Wales (Table 2).
Screening from age 20 years results in eight micro-invasive
cancers diagnosed in age group 20–24 years (Table 4). Estimates
based on observed increases in cervical cancer rates since the
change in policy (scenario 1) resulted in 23 additional cancers
diagnosed in age group 20–26 years (total 73). Of these 73 cancers,
43 (58%) would be micro-invasive. Compared with screening from
age 20 years, under this scenario an extra three frank invasive
cancers were diagnosed corresponding to a rate increase of 0.3 per
100 000 women aged 20–29 years (Table 4). Thus, to prevent one
stage IBþ cancer (under scenario 1), around 39 669 cytology
tests will be carried out and an extra 6794 women will have
non-negative tests, leading to 2723 referrals to colposcopy and 925
women treated. However, to prevent one cancer (of any stage), one
need to do 5156 tests and treat 120 women.
Table 3. Harms and benefits of cervical screening starting from age 20






























Sum 5491 2657 2834
aThe number of non-negative screening episodes is obtained by multiplying the number of
screens by the proportion of women with a non-negative (borderline changes or worse) test.
Table 4. Number of cancers diagnosed in a cohort of 100 000 women
aged 20–26 years (inclusive) under different cancer progression scenarios
















20–24 20.0 14.7 14.0 16.7
25–26 30.0 58.3 36.0 46.9
Sum 50.0 73.1 50.0 63.7
Cancers (stage IA)
20–24 8.0 0.0 0.0 0.0
25–26 14.6 42.6 18.6 26.8
Sum 22.6 42.6 18.6 26.8
Cancers (stage IBþ )
20–24 12.0 14.7 14.0 16.7
25–26 15.4 15.7 17.4 20.2
Sum 27.4 30.4 31.4 36.9
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We have to consider what would happen to cancers screen
detected while micro-invasive under age 25 years (n¼ 8) when
screening does not commence until age 25 years. Under
assumption E, those detected at age 24 years (n¼ 4) would still
be micro-invasive when detected at age 25 years; those detected at
age 23 years (n¼ 2) would have become stage 1B by the time of
detection, at age 25–26 years; and those detected at age 20–22 years
(n¼ 2) would have become symptomatic stage 1B prior to age
25 years. Thus under the assumption that the total number of
cervical cancers diagnosed in the age group 20–26 years remains
the same (scenario 2), there is an overall increase of four frank
invasive cancers in the age group 20–26 years. The additional four
frank invasive cancers represent a 7.3% increase in the age group
20–29 years (assuming all the extra cases are aged 20–26 years)
compared with women invited from age 20 years. Thus, to down-
stage one cancer (under scenario 2), around 29 777 cytology tests
will be carried out, of which around 5100 will be non-negative,
leading to an estimated 2044 referrals to colposcopy and 694
women treated.
Allowing for a rate of 0.2% progression per year from CIN3
(aged 20–24 years) to micro-invasive (scenario 3) resulted in a total
of 13.7 additional cancers: four micro- and nine frank-invasive
(Table 4). This equates to an annual increase in cervical cancer in
women aged 20–29 years of 1.4 per 100 000 women years and the
extra 9.5 stage IBþ cancers to 0.9 per 100 000 women years. Thus,
to prevent one stage IBþ cancer (under scenario 3), around 12 581
cytology tests will be carried out, of which around 2155 will be
non-negative, leading to around 864 referrals to colposcopy and
around 299 women treated.
DISCUSSION
We found that inviting 100 000 women for screening from age 20
years would lead to an extra 119 000 screens, 20 000 extra non-
negative test results, 8000 extra referrals to colposcopy, and extra
3000 women being treated. Compared with starting screening at age
25 years the earlier start may lead to between three and nine fewer
stage IBþ cancers (depending on the scenario). The overall number
of cancers may be reduced by 23.1 but may not change at all. Thus,
to prevent one frank invasive cancer, one would need to do between
12500 and 40 000 additional screening tests in the age group 20–24
years and treat between 300 and 900 women for cervical
intraepithelial neoplasia who would not otherwise be treated.
Our estimates of what happens when 100 000 women are offered
screening from age 20 years are obtained directly from statistics for
Wales and England. As the populations and the screening
programmes in England and Wales may not be directly comparable,
we have always erred on the side of overestimating both the ‘harms’
associated with screening from age 25 years and the benefits of
screening from age 20 years. In this way, our estimates are likely to
put screening from age 20 years in the best possible light. With
around 80% coverage of the HPV vaccination (three doses) in
women born since September 1993 in the United Kingdom, the
balance of harms and benefits of population screening in women
aged 20–24 years will shift further in favour of not screening. We
focus on frank-invasive cancer because many IA cancers (70%) will
be treated by cone excision, which is the same treatment offered to
women diagnosed with CIN3 (Sasieni and Castanon, 2012).
The assumption that screening women aged 20–24 years does
not prevent any cancers in women under the age of 25 years is
supported not only by previously published literature (Sasieni et al,
2003, 2009a) but also by available cancer incidence statistics from
England and Wales. There has been no obvious increase in cervical
cancer aged 20–24 years in England since the change in policy was
introduced (Office for National Statistics, 2013). However, rates in
women aged 25–29 years in 2010 and 2011 in England have
increased and are becoming closer to those observed in Wales.
Case–control data suggest that this increase is due to a large
number of stage IA cancers diagnosed at age 25 years (Castanon
et al, 2013). Nevertheless, it is impossible to assess the full impact
of the change in policy on cancer incidence rates in women aged
25–29 in the most recently available data as all women with cancer
aged 27–29 will have been invited for screening at age 20 years.
Only once women first screened at age 25 years reach the age of 30
years will it be possible to assess whether cancer rates in the age
group 26–29 years have decreased leading to overall rates in the age
group 25–29 years returning to pre-2009 levels despite the
observed increase in cancer at age 25 years.
Given that 5-year relative survival for cervical cancer in England
among women aged 20–39 years is 87.2% (Trent Cancer Registry,
2012) and that 5- and 10-year relative survival for IB cancer (at all
ages) is 88.2% and 83.1%, respectively (Kosary, 2007), it is likely
that at most a small number of women diagnosed with cervical
cancer under age 27 years would die from their disease.
We have not estimated the numbers of cancers in the age group
27–29 years under each scenario because we assume that there will
be no further advantage of starting screening from age 20 years
beyond age 26 years. This is justified because, in recent years, the
majority of women screened between ages 24.5 and 27.5 years in
England are screened between ages 24.75 and 25.5 years (Castanon
et al, 2013). Thus, from age 27 years onwards one is comparing
previously screened women regardless of whether screening starts
at age 20 or 25 years.
The lack of routinely reported data on which to base our
estimates meant that some indirect calculations had to be made.
For example, we do not know the proportion of women with
moderate or worse dyskaryosis in the age group 20–24 years that
are referred to colposcopy, nor do we know how many women are
treated. However, our data are not subject to response or recall bias
and the same method has been used to estimate these numbers in
those screened from age 20 years and from age 25 years.
We have assumed that the relationship between the result of the
cytology and that of the histology are independent of age. However,
results from HPV trials have suggested that women under the age of
30 years who are HPV positive and cytology positive are more likely
to have a histological diagnosis of CIN2 or worse than older women
(Kitchener et al, 2009). This would lead to an even greater excess in
treatment than we have estimated. In addition, there will
undoubtedly be women treated who do not have CIN2 or worse.
On balance, however, we believe that the numbers here will be an
under-estimate of the true numbers receiving treatment.
It is our view that treatment of 300 women by loop excision of the
transformation zone with the ensuing complications (3.8% severe
haemorrhage in a series of 1000 patients treated in Oxford (Hallam
et al, 1993), 0.6% major complications and 9.1% minor complica-
tions according to one US study (Dunn et al, 2004), 67% reporting
pain according to a UK study (Tombola Group et al, 2009)) is not
justified to prevent one case of frank invasive cervical cancer.
The results presented here are specific to the United Kingdom.
As abnormality rates (and cancer incidence rates) vary greatly
between screening programmes, estimates presented here cannot
be extrapolated to other settings. However, where similar data are
available, the methodology used here is generalisable.
CONCLUSION
Estimates of the impact of starting screening at age 25 years
compared with age 20 years are based on the best available data.
Although there is some uncertainty about the numbers of additional
stage IB or worse cancers that are prevented by starting screening
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from age 20 years, it is unlikely to be more than about 1 per 10 000
women population. There is far less uncertainty regarding the
numbers of screening tests, women with abnormal test results, and
women treated at colposcopy as a result of such a policy. To prevent
one stage IB or worse cancer, one would need to do between 12 500
and 40 000 additional screening tests aged 20–24 years and treat
between 300 and 900 women for cervical intraepithelial neoplasia.
It is only with time that we will be able to tell which of these
estimates proves most reasonable. What is clear is that screening
from age 20 years leads to substantial over-treatment and has at
most a modest impact on cervical cancer prevented.
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